Genetic and environmental risk factors for oral anticoagulant overdose

被引:38
作者
Verstuyft, C
Robert, A
Morin, S
Loriot, MA
Flahault, A
Beaune, P
Funck-Brentano, C
Jaillon, P
Becquemont, L
机构
[1] St Antoine Univ 6, Dept Pharmacol, F-75012 Paris, France
[2] Assistance Publ Hop Paris, F-75012 Paris, France
[3] St Antonius Hosp, Dept Immunol & Hematol, F-75012 Paris, France
[4] Univ Paris 05, INSERM U490, Ctr Univ St Peres, Paris, France
[5] Univ Paris 06, Dept Stat, F-75012 Paris, France
关键词
cytochrome P(450)2C9; anticoagulants; overdose; drug interactions; polymorphism genetics; pharmacogenetics;
D O I
10.1007/s00228-002-0538-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Cytochrome P-450 2C9 (CYP2C9) allelic variant carriers have been shown to experience hyper-responsiveness to small doses of oral anticoagulants (OAs) (warfarin or acenocoumarol) and a higher bleeding rate. Objectives: To determine the relative frequencies of different risk factors for OA overdose including diet, concomitant diseases, drug interactions, recent increment of OA dose and CYP2C9 genetic polymorphism among hospitalised patients. Materials and methods: Frequencies of the different risk factors for OA overdose were determined in a prospective case-control study. Seventy-five consecutive patients with an International normalised ratio (INR) greater than 4 were matched with seventy-five control patients with an INR greater than 2 but less than 3.5 with respect to age, prescribed OA and daily dose. Genotyping of CYP2C9*2 and CYP2C9*3 allelic variants was detected by the TaqMan allelic discrimination assay. Results: Drug interactions and a recent increment of OA dose were the only significant independent risk factors identified in the first analysis with odds ratio 2.13 (95% CI: 1.06-4.28) and 3.38 (95%CI: 1.51-7.57), respectively. A recent increment of OA dose was the only significant independent risk factor identified among the patients treated with coumarin derivatives (acenocoumarol or warfarin), excluding those treated with fluindione; the odds ratio was 4.3 (95% CI: 1.5-12.3). CYP2C9 genetic polymorphism did not significantly predict the increased risk of OA overanticoagulation in this study. However three homozygous CYP2C9*3/CYP2C9*3 genotype patients were found among the cases, whereas no such patients could be identified among controls. Conclusion: This is the first observational study investigating the role of CYP2C9 genetic polymorphism together with other environmental OA overdose risk factors. Our results support the view that although the CYP2C9*3/ CYP2C9*3 genotype is associated soon after the introduction of OA with dramatic overanticoagulation, OA overdose is mostly related to environmental factors.
引用
收藏
页码:739 / 745
页数:7
相关论文
共 38 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Warfarin or acenocoumarol: Which is better in the management of oral anticoagulants?
    Barcellona, D
    Vannini, ML
    Fenu, L
    Balestrieri, C
    Marongiu, F
    [J]. THROMBOSIS AND HAEMOSTASIS, 1998, 80 (06) : 899 - 902
  • [3] BIANCO TM, 1992, PHARMACOTHERAPY, V12, P435
  • [4] EXPRESSION OF A HUMAN-LIVER CYTOCHROME-P-450 PROTEIN WITH TOLBUTAMIDE HYDROXYLASE-ACTIVITY IN SACCHAROMYCES-CEREVISIAE
    BRIAN, WR
    SRIVASTAVA, PK
    UMBENHAUER, DR
    LLOYD, RS
    GUENGERICH, FP
    [J]. BIOCHEMISTRY, 1989, 28 (12) : 4993 - 4999
  • [5] CARACO Y, 1989, THROMB HAEMOSTASIS, V62, P906
  • [6] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [7] Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone
    Costedoat-Chalumeau, N
    Amoura, Z
    Aymard, G
    Sevin, O
    Wechsler, B
    Cacoub, P
    Du, LTH
    Diquet, B
    Ankri, A
    Piette, JC
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (08) : 631 - 635
  • [8] RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY
    FIHN, SD
    MCDONELL, M
    MARTIN, D
    HENIKOFF, J
    VERMES, D
    KENT, D
    WHITE, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) : 511 - 520
  • [9] CLINICALLY SIGNIFICANT DRUG-INTERACTIONS WITH THE ORAL ANTICOAGULANTS
    FREEDMAN, MD
    OLATIDOYE, AG
    [J]. DRUG SAFETY, 1994, 10 (05) : 381 - 394
  • [10] Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    Goldstein, JA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 349 - 355